Early stage biotech firm focused on developing microRNA-based diagnostic and therapeutic products, Rosetta Genomics, revised the terms for its IPO Wednesday morning. The company increased the shares offered by 25% to a total of 3.75 million shares, but will be offering them in the range of $7.50-$8.50 which is 33% below its originally filed range of $11.00-$13.00. CE Unterberg Towbin is the lead manager on the deal.
